These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27904819)

  • 1. An overview of Compassionate Use Programs in the European Union member states.
    Balasubramanian G; Morampudi S; Chhabra P; Gowda A; Zomorodi B
    Intractable Rare Dis Res; 2016 Nov; 5(4):244-254. PubMed ID: 27904819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic counselling legislation and practice in cancer in EU Member States.
    McCrary JM; Van Valckenborgh E; Poirel HA; de Putter R; van Rooij J; Horgan D; Dierks ML; Antonova O; Brunet J; Chirita-Emandi A; Colas C; Dalmas M; Ehrencrona H; Grima C; Janavičius R; Klink B; Koczok K; Krajc M; Lace B; Leitsalu L; Mistrik M; Paneque M; Primorac D; Roetzer KM; Ronez J; Slámová L; Spanou E; Stamatopoulos K; Stoklosa T; Strang-Karlsson S; Szakszon K; Szczałuba K; Turner J; van Dooren MF; van Zelst-Stams WAG; Vassallo LM; Wadt KAW; Žigman T; Ripperger T; Genuardi M; Van den Bulcke M; Bergmann AK
    Eur J Public Health; 2024 Jun; ():. PubMed ID: 38905592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical occupational check-ups during the COVID-19 pandemic in the European Union.
    Fošum M; Štěpánek L; Ivanová K; Nakládalová M
    Eur J Public Health; 2024 Jun; ():. PubMed ID: 38894505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Health Interview Survey (EHIS) 2 - Background and study methodology.
    Hintzpeter B; Finger JD; Allen J; Kuhnert R; Seeling S; Thelen J; Lange C
    J Health Monit; 2019 Dec; 4(4):66-79. PubMed ID: 35146260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action.
    Anderson M; Towse A; Outterson K; Mossialos E
    Lancet Microbe; 2024 Jun; ():. PubMed ID: 38885690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulations and guidelines governing stem cell based products: Clinical considerations.
    George B
    Perspect Clin Res; 2011 Jul; 2(3):94-9. PubMed ID: 21897884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Can Big Data Offer the Pharmacovigilance of Orphan Drugs?
    Price J
    Clin Ther; 2016 Dec; 38(12):2533-2545. PubMed ID: 27914633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
    Borysowski J; Górski A
    Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre.
    Cronin TK; Ronayne C; O'Donovan N; McGuinness E; Cooke K; Dennehy M; Dennehy C; Power DG; Cahill MR; Collins DC; Connolly RM; Bambury RM; Mykytiv V; Higgins MJ; Noonan SA; O'Reilly S
    Ir J Med Sci; 2024 May; ():. PubMed ID: 38806877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising oncology drug expenditure in Ireland.
    Kieran R; Hennessy M; Coakley K; O'Sullivan H; Cronin T; Lynch D; Mulroe E; Cooke K; Collins D; O'Reilly S
    Ir J Med Sci; 2024 Apr; ():. PubMed ID: 38568369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis.
    Vermeulen SF; Hordijk M; Visser RJ; Bunnik EM
    J Law Med Ethics; 2023; 51(1):172-180. PubMed ID: 37226748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.
    Luyendijk M; Blommestein H; Uyl-de Groot C; Siesling S; Jager A
    JAMA Netw Open; 2023 Feb; 6(2):e2256170. PubMed ID: 36795415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
    Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
    Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.
    Krendyukov A; Singhvi S; Green-Morrison Y; Zabransky M
    Front Oncol; 2022; 12():714516. PubMed ID: 36387084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions.
    Aliu P; Sarp S; Reichenbach R; Behr S; Fitzsimmons P; Shamlajee M; Kola SP; Nunes Radimerski S; Scosyrev E
    JAMA Health Forum; 2022 Apr; 3(4):e220475. PubMed ID: 35977322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.
    Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA; Darrow JJ
    Front Pharmacol; 2022; 13():913567. PubMed ID: 35677436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
    Maeda H; Uchida M; Kusano M; Tsukamoto K; Yamanoi M
    Clin Pharmacol Ther; 2022 Oct; 112(4):817-823. PubMed ID: 35569010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.
    Jandhyala R
    J Pharm Policy Pract; 2022 May; 15(1):36. PubMed ID: 35509059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
    Kong FC; Yu M; Zhou YL; Wang SX; Li F
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):66-69. PubMed ID: 35231996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.